receiving coumarin anticoagulant therapy Current perspectives on dental patients
Q nticoagulation with coumarin, which is prescribed for more than 1 million people in the United States each year,' presents the most common potential bleeding problem that dentists encounter. Dental care for a patient receiving anticoagulant therapy requires balancing the opposing risks of significant hemorrhage from procedures against the potential for thromboembolism from reducing or withdrawing anticoagulant therapy.2 Despite approximately 40 years of experience with oral anticoagulant drugs, dentists and physicians differ widely in their opinions about which patients can be safely treated without modification of anticoagulation status and about which dental procedures pose a risk to the patient.3 '4 In an attempt to clarify these issues, we examine the safety of dental treatment for patients receiving anticoagulant therapy. We review how coumarin affects coagulation, present the newly accepted international normalized ratio, or monitoring anticoagulation status and describe current medical practice with respect to the use of coumarin. To assist practitioners who see these patients, we offer detailed recommendations for the dental management of people receiving coumarin anticoagulant therapy. COUMARIN toring schedule and whether frequent dosage modification is necessary. Second, through standard evaluation techniques, the dentist should determine the required types of therapy, with special consideration given to the potential for hemorrhage. Factors affecting risk assessment include the presence of gingival inflammation and periodontitis, need for surgical intervention, need for block anesthesia and number of anticipated treatment visits.
If the duration of anticoagulant therapy is anticipated to be six months or less (common with deep venous thrombosis), the dentist may want to postpone elective care until after the normal cessation of anticoagulant therapy. This is especially true if nonurgent surgery is part of the proposed treatment. However, urgent treatment needs may preclude deferral for any substantial period.
Consultation. Consultation with the patient's physician is an essential step in dental management. During the conversation with the physician, the dentist should verify the information obtained from the patient and obtain the current PT/INR values. The dentist should also describe the anticipated dental treatment. However, in our opinion, it is the responsibility of the dentist to determine if the anticipated care can be accomplished without modifying the patient's anticoagulant therapy and to express this to the physician. Physicians do not have the expertise to evaluate the degree of difficulty, invasiveness, potential morbidity, expected blood loss or other attendant hemorrhagic risks for most dental procedures. While, ultimately, the physician determines whether anticoagulant therapy is to be modified, dentists must be the content experts on dental therapy and its risks.
Testing. Before dental procedures are initiated, it is essential that the patient's anticoagulation status, as measured by a current PT/INR, be known. While hospital-based practitioners may prefer to order these tests, the majority of dentists usually refer patients to the attending physician for testing. (Figure 1) .
Partial reduction or interruption of anticoagulant therapy. If needed to minimize hemorrhagic risk, the patient's anticoagulation status (INR) may be shifted temporarily to the low end of the therapeutic target range or into a suboptimal range. The most practical way of accomplishing this is by a two-or three-day withdrawal protocol (Figure 2) .3536 This results in improved hemostasis and keeps the duration of reduced anticoagulation to a minimum.27 For most patients, a two-day withdrawal is adequate, but if the patient is aged or has a high INR, the threeday protocol may be necessary.
Cessation ofanticoagulant therapy. Another option is to stop coumarin therapy for four or five days before performing dental treatment, which is sufficient time for the effects of the drug to be eliminated.57 Coumarin 
